Used primarily in research settings for its potential as a sigma receptor antagonist, particularly targeting sigma-1 and sigma-2 receptors. These receptors are implicated in neurological and psychiatric disorders, making rimcazole dihydrochloride a compound of interest in studying conditions such as depression, anxiety, and psychosis. It has also been investigated for its possible neuroprotective properties and role in modulating dopamine activity, suggesting potential relevance in Parkinson’s disease and substance abuse research. Additionally, due to its interaction with sigma receptors involved in cancer cell proliferation, it has been explored in oncology-related studies, though it remains strictly a research compound with no approved clinical therapeutics to date.